bluebird bio to split into oncology and gene therapy specialistsUS biotech bluebird bio has announced plans to split into two this year, with a separate oncology business Share Xbluebird bio to split into oncology and gene therapy specialistshttps://pharmaphorum.com/news/bluebird-bio-to-split-into-oncology-and-gene-therapy-specialists/
2020 in review: Pharma’s progress outside of COVID-19It has been a year dominated by the pandemic and many life sciences research projects were put on Share X2020 in review: Pharma’s progress outside of COVID-19https://pharmaphorum.com/views-analysis-oncology/2020-review-pharmas-progress-outside-of-covid-19/
Tay-Sachs and rare disease registries – the Health Heroes podcastEpisode four of Kantar Health’s Health Heroes podcast tackles pharma’s rare disease challenges, the role of patient registries Share XTay-Sachs and rare disease registries – the Health Heroes podcasthttps://pharmaphorum.com/podcast/rare-disease-registries-kantar-health/
Operationalize: Expanded Access Programs SummitOperational Expanded Access Programs Summit Share XOperationalize: Expanded Access Programs Summithttps://pharmaphorum.com/events/operationalize-expanded-access-programs-summit/
Rocket Pharmaceuticals in orbit after gene therapy read-outShares in Rocket Pharmaceuticals have been living up to their name, shooting up following encouraging early-stage clinical trial Share XRocket Pharmaceuticals in orbit after gene therapy read-outhttps://pharmaphorum.com/news/rocket-pharmaceuticals-shares-go-into-orbit-after-gene-therapy-read-out/
The urgent need for education and awareness about mitochondrial diseaseDelayed diagnosis, misdiagnosis, and no cure or disease modifying treatments – children living with mitochondrial disease face all Share XThe urgent need for education and awareness about mitochondrial diseasehttps://pharmaphorum.com/views-and-analysis/the-urgent-need-for-education-and-awareness-about-mitochondrial-disease/
Biotech trends in COVID era: the pharmaphorum podcastIn episode 26 the pharmaphorum podcast hears from David Solomon, a 30-year life sciences industry veteran who recently Share XBiotech trends in COVID era: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/biotech-trends-pharnext-david-solomon/
‘Knowledge is power’ for rare diseases and NAbsCure Rare Disease’s Rich Horgan discusses the importance of NAbs screening and helping rare disease patients better understand Share X‘Knowledge is power’ for rare diseases and NAbshttps://pharmaphorum.com/views-analysis-patients/knowledge-is-power-for-rare-diseases-and-nabs/
How the rare disease community has developed fertile ground for progressAmanda Barrell explores how a perfect storm of changing economics, advances in technology, and the increasing volume of Share XHow the rare disease community has developed fertile ground for progresshttps://pharmaphorum.com/views-analysis-patients/how-the-community-developed-fertile-ground-for-progress-in-rare-disease-drug-development/